Beverly M. K. Biller

Harvard University — United States

Medicine · Health Sciences

75h-index23.5kcitations490works4.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pituitary Gland Disorders and Treatments(224), Growth Hormone and Insulin-like Growth Factors(184), Adrenal Hormones and Disorders(97), Adrenal and Paraganglionic Tumors(71), Lipid metabolism and disorders(24)

Publications488 total

Clinical Pearls From <i>JCEM Case Reports</i>: ENDO 2025.
PubMed·2025Open Access
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment
The Journal of Clinical Endocrinology & Metabolism·2025· 2 citedOpen Access
Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4
European Journal of Endocrinology·2025· 4 citedOpen Access
OR12-07 Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension
Journal of the Endocrine Society·2025· 1 citedOpen Access
SUN-072 The Role of Late-Night Salivary Cortisol in Evaluating Endocrine Remission in Patients With Cushing’s Disease Following Pituitary Radiotherapy: A Retrospective Cohort Analysis
Journal of the Endocrine Society·2025Open Access
SUN-097 CAM2029 Octreotide Subcutaneous Depot Maintains Control of IGF-I and Symptoms of Acromegaly Across the 4-Week Dosing Interval and During Intervals Greater Than 28 Days: Data from the ACROINNOVA 1 Trial
Journal of the Endocrine Society·2025Open Access
MON-069 Once-daily Oral Paltusotine In The Treatment Of Patients With Biochemically Uncontrolled Acromegaly: Interim Results Of The PATHFNDR-2 Open-label Extension
Journal of the Endocrine Society·2025· 1 citedOpen Access
Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis
Endocrine Connections·2025Open Access
Consensus on acromegaly therapeutic outcomes: an update
Nature Reviews Endocrinology·2025· 19 citedOpen Access
Development of a Minimum Dataset for the Global Monitoring of the Safety and Efficacy of Growth Hormone Replacement in Adults With Growth Hormone Deficiency (AGHD)
Clinical Endocrinology·2025Open Access
Correction to: Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies
Pituitary·2025· 2 citedOpen Access
The Role of Late‐Night Salivary Cortisol in the Assessment of Endocrine Remission in Patients With Cushing's Disease After Pituitary Radiotherapy
Clinical Endocrinology·2025
Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society
Pituitary·2025· 5 cited
Osilodrostat Treatment for Adrenal and Ectopic Cushing Syndrome: Integration of Clinical Studies With Case Presentations
Journal of the Endocrine Society·2025· 12 citedOpen Access
Osilodrostat improves blood pressure and glycemic control in patients with Cushing’s disease: a pooled analysis of LINC 3 and LINC 4 studies
Pituitary·2025· 11 citedOpen Access
Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
UNC Libraries·2025Open Access
Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation
UNC Libraries·2025Open Access
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
UNC Libraries·2025· 2 citedOpen Access
Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol
Journal of the Endocrine Society·2024· 13 citedOpen Access
7790 A Non-interventional, Multinational, Phase IV Study to Evaluate the Long-Term Safety and Efficacy of Osilodrostat in Patients with Endogenous Cushing's Syndrome (LINC 6): 1-Year Real-World Interim Analysis
Journal of the Endocrine Society·2024· 2 citedOpen Access
page 1 of 25Next →

Frequent Co-authors

Anne Klibanski(13), Maria Fleseriu(11), Brooke Swearingen(10), Шломо Мелмед(9), Stephan Petersenn(9), Laurence Katznelson(9), James W. Findling(8), John Newell‐Price(8), Mark E. Molitch(8), Rosario Pivonello(7), Anne Klibanski(7), Christian J. Strasburger(7), Mônica R. Gadelha(6), Ken K. Y. Ho(6), Kevin C.J. Yuen(6), John Wass(5), Marcello D. Bronstein(5), Felipe F. Casanueva(5), Philippe Chanson(5), Andrea Giustina(5)